Johnson & Johnson
NYSE:JNJ

Watchlist Manager
Johnson & Johnson Logo
Johnson & Johnson
NYSE:JNJ
Watchlist
Price: 145.85 USD 0.4% Market Closed
Market Cap: 351.2B USD
Have any thoughts about
Johnson & Johnson?
Write Note

Johnson & Johnson
Total Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Johnson & Johnson
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
Johnson & Johnson
NYSE:JNJ
Total Current Assets
$53.2B
CAGR 3-Years
-4%
CAGR 5-Years
4%
CAGR 10-Years
-1%
Bristol-Myers Squibb Co
NYSE:BMY
Total Current Assets
$28.1B
CAGR 3-Years
-4%
CAGR 5-Years
-7%
CAGR 10-Years
7%
Pfizer Inc
NYSE:PFE
Total Current Assets
$37.8B
CAGR 3-Years
-13%
CAGR 5-Years
2%
CAGR 10-Years
-4%
Merck & Co Inc
NYSE:MRK
Total Current Assets
$40.4B
CAGR 3-Years
9%
CAGR 5-Years
9%
CAGR 10-Years
2%
Zoetis Inc
NYSE:ZTS
Total Current Assets
$6.3B
CAGR 3-Years
-2%
CAGR 5-Years
6%
CAGR 10-Years
6%
Eli Lilly and Co
NYSE:LLY
Total Current Assets
$31.4B
CAGR 3-Years
21%
CAGR 5-Years
20%
CAGR 10-Years
10%
No Stocks Found

Johnson & Johnson
Glance View

Market Cap
351.1B USD
Industry
Pharmaceuticals
Economic Moat
Wide

Founded in 1886, Johnson & Johnson began its journey with a commitment to revolutionizing healthcare, starting with the sterile surgical dressings it produced to reduce infections in hospitals. Over the decades, this vision expanded into a global healthcare powerhouse, intricate in its operation yet unified in its mission to improve lives. Johnson & Johnson's business model is built on three core segments: pharmaceuticals, medical devices, and consumer health products. Each segment harnesses the synergy of innovation, research, and a deep understanding of customer needs. The pharmaceutical division, one of its most robust, thrives on producing treatments for various medical conditions, including immunology, oncology, and neuroscience. It is in this domain that cutting-edge research and development efforts translate into high-margin therapies, driving substantial portions of the company's revenue. Beyond pharmaceuticals, the medical devices segment forms a pillar of Johnson & Johnson's operations, offering a spectrum of products essential for surgeries, orthopedics, and vision care. These devices are integral for modern healthcare practices, with their premium positioning contributing significantly to the company’s financial health. Meanwhile, Johnson & Johnson's consumer health division addresses everyday wellness needs, with iconic brands like Band-Aid, Tylenol, and Neutrogena. This segment leverages global brand recognition and trust to generate steady, albeit lower-margin, income streams. Together, these segments compose a diversified revenue platform, buffered against sector-specific downturns and positioning Johnson & Johnson as a formidable entity in global healthcare markets.

JNJ Intrinsic Value
155.23 USD
Undervaluation 6%
Intrinsic Value
Price

See Also

What is Johnson & Johnson's Total Current Assets?
Total Current Assets
53.2B USD

Based on the financial report for Sep 29, 2024, Johnson & Johnson's Total Current Assets amounts to 53.2B USD.

What is Johnson & Johnson's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
-1%

Over the last year, the Total Current Assets growth was -1%. The average annual Total Current Assets growth rates for Johnson & Johnson have been -4% over the past three years , 4% over the past five years , and -1% over the past ten years .

Back to Top